Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
8 key takeaways from Savannah Guthrie's 'Today' interview on the disappearance of her mother - 2Most loved Public Dish: Which One Addresses Its Nation Best?
- 3'I carried my wife's body for an hour and a half' - BBC hears stories of protesters killed in Iran
- 4Hundreds of kilos of protected plant seized by Israel Nature and Parks Authority in Golan
- 5Change Your Skincare: 10 Inventive Magnificence Gadgets
- Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
- New science points to 4 distinct types of autism
- Ukrainian man arrested in Germany on suspicion of spying for Russia
- Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- Iran begins cloud seeding to induce rain amid historic drought
- Israel's haredi draft crisis: Court ruling and political stalemate reach breaking point
- Why home maintenance deserves a spot in the annual health and budget plans
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- A definitive Bike Standoff: Decision in favor of Your Number one Ride
